Table 1. Characterization of anti-HBsAg antibodies.
| Antibody | Affinity KD(M) a | Epitopeb | Neutralization activityc | Antibody | Affinity KD(M) a | Epitopeb | Neutralization activityc |
|---|---|---|---|---|---|---|---|
| A3E3 | 5.67×10−8 | 3 | ++ | D12H12 | 2.04×10−7 | 2 | ++ |
| A5E5 | 3.75×10−9 | 4 | -/+ | 2A1E1 | 2.39×10−9 | 4 | -/+ |
| A6E6 | 3.24×10−8 | ND | + | 2A2E2 | 3.72×10−8 | 3 | ++ |
| A7E7 | 6.64×10−9 | 1 | -/+ | 2A9E9 | 4.35×10−8 | ND | -/+ |
| A10E10 | 2.12×10−8 | 2 | + | 2B4F4 | 1.71×10−9 | 2 | ++ |
| A11E11 | 5.63×10−8 | 1 | -/+ | 2B5F5 | 6.63×10−8 | 2 | + |
| B1F1 | 2.95×10−7 | 2 | ++ | 2B6F6 | 5.11×10−8 | 3 | ++ |
| B6F6 | 4.82×10−8 | 2 | ND | 2B10F10 | 8.35×10−9 | 4 | ++ |
| B7F7 | 6.55×10−9 | 3 | -/+ | 2B11F11 | 6.28×10−8 | ND | -/+ |
| B9F9 | 2.86×10−9 | 4 | ++ | 2C2G2 | 1.77×10−7 | 2 | + |
| B12F12 | 1.33×10−8 | 3 | + | 2C3G3 | 3.66×10−8 | ND | -/+ |
| C1G1 | 6.74×10−7 | 3 | ND | 2C5G5 | 3.28×10−9 | 2 | + |
| C2G2 | 1.85×10−9 | 2 | ++ | 2C6G6 | 1.11×10−8 | 3 | ++ |
| C4G4 | 3.66×10−9 | 2 | ++ | 2C7G7 | 8.6×10−8 | 3 | + |
| C8G8 | 3.03×10−7 | 2 | -/+ | 2C8G8 | 8.28×10−7 | 3 | ++ |
| C9G9 | 3.81×10−8 | ND | + | 2D1H1 | 5.04×10−8 | 1 | ++ |
| D2H2 | 5.82×10−9 | 3 | ++ | 2D4H4 | 3.48×10−9 | 2 | ++ |
| D3H3 | 4.14×10−8 | 2 | ND | 2D5H5 | 2.73×10−7 | 2 | ND |
| D5H5 | 1.88×10−9 | 2 | ++ | 2D8H8 | 2.12×10−8 | 3 | ++ |
| D6H6 | 4.86×10−7 | 3 | ++ | 2D9H9 | 5.29×10−8 | 3 | + |
| D10H10 | 1.58×10−8 | 2 | + | C4D2-BsAb | 3.88×10−9 | 2,3 | ++ |
| D11H11 | 8.92×10−9 | ND | -/+ | D2C4-BsAb | 4.95×10−9 | 2,3 |
a Affinities were analyzed with ELISA. bEpitopes were analyzed by ELISA using synthesized peptides (P1, amino acids 104–120; P2, amino acids 121–137; P3, amino acids 139–148; P4, amino acids 149–163) covering extracellular domain of HBsAg. cHBV-neutralization activity : ++, more than 60% inhibition; +, 40%–60% inhibition; –/+, 20-40% inhibition at day 7 post-infection from that with control IgG. ND, not determined.